Top

Published in:

Open Access 01-12-2014 | Case report

Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report

Authors: Sayaka Ohara, Tomonori Ushijima, Mariko Gunji, Chiharu Tanai, Yoshiaki Tanaka, Hiromichi Noda, Hajime Horiuchi, Kazuhiro Usui

Published in: Journal of Medical Case Reports | Issue 1/2014

Abstract

Introduction

Non-small-cell lung cancer harboring an activated epidermal growth factor receptor mutation exhibits a good response to epidermal growth factor receptor-tyrosine kinase inhibitors; however, clinicians often experience treatment failure following the development of resistance to epidermal growth factor receptor-tyrosine kinase inhibitor.

Case presentation

We here report a case of a 56-year-old Japanese woman with non-small-cell lung carcinoma with a secondary T790M mutation associated with resistance to epidermal growth factor receptor-tyrosine kinase inhibitor that maintained sensitivity of brain metastases to epidermal growth factor receptor-tyrosine kinase inhibitor. An autopsy showed that the primary focus had a T790M mutation; however, no mutations of T790M were found in the brain metastases.

Conclusion

This case demonstrates the detection of T790M was associated with the clinical responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor.

Available only for authorised users

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500. 10.1126/science.1099314.CrossRefPubMed

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056/NEJMoa040938.CrossRefPubMed

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005, 352: 786-792. 10.1056/NEJMoa044238.CrossRefPubMed

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2: e73-10.1371/journal.pmed.0020073.CrossRefPubMedPubMedCentral

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007, 316: 1039-1043. 10.1126/science.1141478.CrossRefPubMed

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007, 104: 20932-20937. 10.1073/pnas.0710370104.CrossRefPubMedPubMedCentral

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68 (22): 9479-9487. 10.1158/0008-5472.CAN-08-1643.CrossRefPubMed

Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, Tanaka T, Miyazawa H, Nagata M, Kanazawa M, Hagiwara K, Kobayashi K: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer. 2006, 95: 1483-1489. 10.1038/sj.bjc.6603466.CrossRefPubMedPubMedCentral

Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H: Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007, 242: 882-888. 10.1148/radiol.2423051707.CrossRefPubMed

10.

Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004, 22: 2865-2872. 10.1200/JCO.2004.12.149.CrossRefPubMed

11.

Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005, 103 (11): 2344-2348. 10.1002/cncr.21033.CrossRefPubMed

12.

Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV: EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010, 12 (11): 1193-1199. 10.1093/neuonc/noq076.CrossRefPubMedPubMedCentral

13.

Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012, 77 (3): 556-560. 10.1016/j.lungcan.2012.05.092.CrossRefPubMed

14.

Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE: Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006, 24 (27): 4517-4520. 10.1200/JCO.2006.06.6126.CrossRefPubMed

15.

Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J. 2009, 33: 436-440.CrossRefPubMed

Title: Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report
Authors: Sayaka Ohara
Tomonori Ushijima
Mariko Gunji
Chiharu Tanai
Yoshiaki Tanaka
Hiromichi Noda
Hajime Horiuchi
Kazuhiro Usui
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/1752-1947-8-64

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report

Abstract

Introduction

Case presentation

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Ruptured subscapular artery aneurysm and subclavian artery occlusion in a patient with type 1 neurofibromatosis: a case report

Necrotizing fasciitis – a diagnostic dilemma: two case reports

Community-acquired methicillin-resistant Staphylococcus epidermidis pyelonephritis in a child: a case report

Acute monolateral proptosis and orbital myositis in a patient with discoid lupus erythematosus: a case report

Giant schwannoma with extensive scalloping of the lumbar vertebral body treated with one-stage posterior surgery: a case report

An aggressive vertebral hemangioma in pregnancy: a case report